The patient achieved sustained disease stabilization following therapeutic dose modification of orelabrutinib, representing the first evidence-based documentation that Bruton’s tyrosine kinase (BTK) inhibitor down-titration confers clinical efficacy in PTLD. The gene discussed is BTK; the disease is post-transplant lymphoproliferative disease.